

Appendix 4D

(Rule 4.2A.3)

Half year report

Name of entity

Nanoveu Limited	97 624 421 085
-----------------	----------------

1. Details of the Reporting Period and the Previous Corresponding Period

Financial period ended ("current period")	Financial period ended ("previous period")
30 June 2022	30 June 2021

2. Results for Announcement to the Market

			\$'000	%		\$'000
2.1	Revenue from ordinary activities	down	347	82%	to	77
2.2	Loss from ordinary activities after tax attributable to members	up	219	14%	to	1,227
2.3	Net loss for the period attributable to members	up	219	14%	to	1,227
2.4	Loss per share	down		19%	to	0.6 cents
2.5	Brief explanation of results					
	<p>During the period Nanoveu has continued to focus on its antiviral business. Key developments have included:</p> <ul style="list-style-type: none"> • Launch of Nanoshield™ Bot - a Robot as a Service ("RaaS") based disinfection robot that dispenses a fine mist of the Company's newly launched e-water, which contains Complex Oxygen Compounds with excellent antiviral and antibacterial efficacy¹. • Nanoveu launched 'Liquid Film', a spray on version of the Company's antimicrobial surface protection films, with the product achieving a >99.99% reduction of MHV-A59 (a surrogate for COVID-19) within 10 minutes². • Liquid Film was listed by the Singapore National Environmental Agency (NEA) as a Self-Disinfecting Surface Coating Product Effective Against Coronaviruses². 					

¹ Refer ASX announcement of 16 March 2022 for the testing performed and the results.

² Refer ASX announcement of 9 February 2022 for the testing performed and the results.

	<ul style="list-style-type: none"> Nanoshield™ Antiviral Liquid Spray listed by the Singapore National Environmental Agency (NEA) as a Self-Disinfecting Surface Coating Product Effective Against Coronaviruses². Nanoshield™ Antiviral Film product was accepted as Class I medical device with the UK based Medicines and Healthcare products Regulatory Agency (MHRA). Nanoveu and Alan Scott Industries Ltd (Alan Scott) have signed a memorandum of understanding (MoU) to establish a new company to be called Alan Scott Nanoveu India Limited (ASNIL) which will have a paid-up capital of US\$200,000 and be 35% owned by Nanoveu. The MoU shall terminate on 31 December 2022 unless agreed otherwise by the parties. Commercial terms will be negotiated and finalised during the period the MoU is in place following which a definitive agreement is expected to be signed which will see ASNIL buy Nanoshield products from Nanoveu and sell these in India utilising Alan Scott’s existing networks and retail outlets. <p>For further details, please refer to the interim financial report.</p>
--	---

3. NTA Backing

	Current period	Previous corresponding period
Net tangible asset backing per ordinary security	\$0.0033	\$0.0052

4 Control gained or lost over entities having material effect

Not applicable.

5. Dividends

There were no dividends declared or paid during the period and the do not recommend that any dividends be paid.

6. Dividend Reinvestment Plans

Not applicable.

7. Material interest in entities which are not controlled entities

Not applicable.

8. Independent Review Report

Refer to the attached Half Year Financial Report for the half-year ended 30 June 2022.

9. Compliance Statement

This report should be read in conjunction with the attached Half-year Financial Report for the half-year ended 30 June 2022.



Signed here:

Date: 31 August 2022

Print name: Alfred Chong
Managing Director and CEO



Nanoveu Limited

(ACN 624 421 085)

**INTERIM FINANCIAL REPORT
FOR THE HALF-YEAR ENDED**

30 June 2022

CONTENTS	PAGE
Company Directory	1
Letter from the Managing Director and CEO	2
Directors' Report	3
Auditor's Independence Declaration	5
Consolidated Statement of Profit or Loss and Other Comprehensive Income	6
Consolidated Statement of Financial Position	7
Consolidated Statement of Changes in Equity	8
Consolidated Statement of Cash Flows	9
Notes to the Consolidated Financial Statements	10 – 17
Directors' Declaration	18
Independent Auditor's Review Report	19

COMPANY DIRECTORY

Directors

Mr Alfred Chong
Managing Director

Mr Michael van Uffelen
Executive Director

Mr Steven Apedaile
Non-executive Director

Mr Scott Beeton
Non-executive Chairman

Company Secretary

Mr Michael van Uffelen

Share Registry

Automic Registry Services
Level 2
267 St Georges Terrace
Perth WA 6000

Telephone (within Australia): 1300 288 664
Telephone (outside Australia): +61 2 9698 5414

Email: hello@automic.com.au

ABN:

97 624 421 085

Registered Office

1/18 Olive Street
Subiaco WA 6008

Tel: +61 8 6244 9095

Web Address

www.nanoveu.com

ASX Code:

NVU

Auditors

BDO Audit (WA) Pty Ltd
Level 9
Mia Yellagonga Tower 2
5 Spring Street
Perth WA 6000
AUSTRALIA

Solicitors

Steinepreis Paganin
Level 4, The Read Buildings
16 Milligan Street
Perth WA 6000

LETTER FROM THE MANAGING DIRECTOR AND CEO

Dear Shareholders,

A warm welcome to our half year results. As we transition towards a post pandemic era, Nanoveu is firmly poised to become the world leader in providing solutions for infectious disease control as we work on opportunities for businesses that still view curbing the spread of disease integral to their operations such as Hospital, Airports, Schools and public locations.

During the period Nanoveu has continued to focus on its antiviral business. Key developments have included:

- Launch of Nanoshield™ Bot - a Robot as a Service (“RaaS”) based disinfection robot that dispenses a fine mist of the Company’s newly launched e-water, which contains Complex Oxygen Compounds with excellent antiviral and antibacterial efficacy¹.
- Nanoveu launched ‘Liquid Film’, a spray on version of the Company’s antimicrobial surface protection films, with the product achieving a >99.99% reduction of MHV-A59 (a surrogate for COVID-19) within 10 minutes².
- Liquid Film was listed by the Singapore National Environmental Agency (NEA) as a Self-Disinfecting Surface Coating Product Effective Against Coronaviruses².
- Nanoshield™ Antiviral Liquid Spray listed by the Singapore National Environmental Agency (NEA) as a Self-Disinfecting Surface Coating Product Effective Against Coronaviruses².
- Nanoshield™ Antiviral Film product was accepted as Class I medical device with the UK based Medicines and Healthcare products Regulatory Agency (MHRA).
- Nanoveu and Alan Scott Industries Ltd (Alan Scott) have signed a memorandum of understanding (MoU) to establish a new company to be called Alan Scott Nanoveu India Limited (ASNIL) which will have a paid-up capital of US\$200,000 and be 35% owned by Nanoveu. The MoU shall terminate on 31 December 2022 unless agreed otherwise by the parties. Commercial terms will be negotiated and finalised during the period the MoU is in place following which a definitive agreement is expected to be signed which will see ASNIL buy Nanoshield products from Nanoveu and sell these in India utilising Alan Scott’s existing networks and retail outlets.

On behalf of the Board I would like to thank all shareholders, staff and stakeholders across Nanoveu. We continue to work hard to maximise the potential of our products and returns to shareholders.

I would also like to thank Mr David Nicol for his services as a director of Nanoveu prior to his retirement in March 2022.



Alfred Chong

Managing Director and CEO

¹ Refer ASX announcement of 16 March 2022 for the testing performed and the results.

² Refer ASX announcement of 9 February 2022 for the testing performed and the results.

DIRECTORS' REPORT

Your Directors submit the financial report of the Company, being Nanoveu Limited, and the entities it controlled ("the Group"), for the half-year ended 30 June 2022. In order to comply with the provisions of the Corporations Act 2001, the Directors report as follows:

Directors

The names of Directors who held office during or since the end of the half-year and until the date of this report are as below. Directors were in office for this entire period unless otherwise stated.

Alfred Chong	Managing Director and CEO
Michael van Uffelen	Executive Director, Company Secretary and CFO
Steven Apedaile	Independent Non-executive Director
David Nicol	Independent Non-executive Director (resigned effective 2 March 2022)
Scott Beeton	Chairman, Independent Non-executive Director (Resigned effective 31 August 2022)

Review of Operations

The loss for the half-year period for the Group after providing for income tax amounted to \$1,227,000 (2021: \$1,077,573).

We are technology innovators who specialise in modern, cutting-edge nanotechnology that improve the way we live, from reducing contagious transmissions on high touch points to immersive vision-based entertainment. <https://www.nanoveu.com/>

Nanoshield - is a film which uses a patented polymer of Cuprous embedded film to self-disinfect surfaces. Nanoshield antiviral protection which is available in a variety of shapes and forms, from mobile screen covers, to mobile phone cases and as a PVC commercial film, capable of being applied to a number of surfaces such as doorhandles and push panels. The perfectly clear plastic film contains a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. This technology is also being applied to fabric applications targeting use in the personal protective equipment sector.

EyeFly3D - is a film applied to digital displays that allowed users to experience 3D without the need for glasses on everyday mobile handheld devices.

Customskins - are vending machines capable of precisely applying screen covers to mobile phones with an alignment accuracy of 150 microns.

EyeFyx - currently in research and development stage, EyeFyx is a vision correction solution using hardware and software to manipulate screen output addressing long-sightedness without the need to wear reading glasses.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the Group during the financial half-year.

Events After Reporting Date

Subsequent to reporting date the Company issued 10,714,286 shares at \$0.014 retiring \$150,000 of debt of the Company and Non-executive director, Mr Scott Beeton, retired effective 31 August 2022.

The impact of the Coronavirus (COVID-19) pandemic is ongoing and it is not practicable to estimate the potential impact, positive or negative, after the reporting period. The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

DIRECTORS' REPORT

Apart from the item above, no matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs in future financial years.

Auditor's Independence Declaration

Section 307C of the Corporations Act 2001 requires our auditors, BDO Audit (WA) Pty Ltd, to provide the Directors of the Company with an Independence Declaration in relation to the review of the half-year financial report. This Independence Declaration is set out on page 5 and forms part of this Directors' report for the half-year ended 30 June 2022.

This report is signed in accordance with a resolution of the Board of Directors made pursuant to section 306(3)(a) of the Corporations Act 2001.



Mr Alfred Chong
Managing Director and CEO


Dated this 31st day of August 2022

DECLARATION OF INDEPENDENCE BY JACKSON WHEELER TO THE DIRECTORS OF NANOVEU LIMITED

As lead auditor for the review of Nanoveu Limited for the half-year ended 30 June 2022, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Nanoveu Limited and the entities it controlled during the period.



Jackson Wheeler

Director

BDO Audit (WA) Pty Ltd

Perth

31 August 2022

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

HALF-YEAR ENDED 30 JUNE 2022

	Note	Half-Year Ended 30/06/2022 \$	Half-Year Ended 30/06/2021 \$
Revenue from contracts with customers		77,187	423,827
Revenue		77,187	423,827
Cost of sale of goods		(17,568)	(174,583)
Gross profit		59,619	249,244
Other operating income		19,369	50,299
Selling and distribution expenses		(195,325)	(407,473)
Administration expenses		(721,296)	(623,922)
Research and development costs		(199,366)	(86,056)
Share based payment expense	8	(16,977)	(117,543)
Impairment expense	11	(100,724)	-
Operating loss		(1,154,699)	(935,451)
Finance income		76	262
Finance costs		(72,377)	(142,384)
Loss before income tax		(1,227,000)	(1,077,573)
Income tax expense		-	-
Loss for the period		(1,227,000)	(1,077,573)
Other comprehensive income / (loss)			
<i>Items that may be reclassified to profit or loss:</i>			
- Currency translation differences arising from consolidation		1,737	3,267
		1,737	3,267
Total comprehensive loss for the period		(1,225,263)	(1,074,306)
Loss per share – basic and diluted	3	(0.6)	(0.7)

The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2022

	Note	30 June 2022 \$	31 December 2021 \$
CURRENT ASSETS			
Cash and cash equivalents		962,862	2,013,375
Trade and other receivables		34,383	205,961
Inventories	5	545,618	469,298
Total Current Assets		1,542,863	2,688,634
NON-CURRENT ASSETS			
Plant and equipment		79,118	64,955
Total Non-current Assets		79,118	64,955
TOTAL ASSETS		1,606,799	2,753,589
CURRENT LIABILITIES			
Trade and other payables		143,287	161,409
Financial liability	6	709,059	986,682
Provisions		29,949	20,895
Total Current Liabilities		882,295	1,168,986
TOTAL LIABILITIES		882,295	1,168,986
NET ASSETS		724,504	1,584,603
EQUITY			
Issued capital	7	17,117,626	16,769,439
Accumulated losses		(15,496,349)	(14,269,349)
Reserves		(896,773)	(915,487)
TOTAL EQUITY		724,504	1,584,603

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

HALF-YEAR ENDED 30 JUNE 2022

	Issued Capital	Accumulated Losses	Option Reserve	Common Control Reserve	Share Based Payment Reserve	Foreign Currency Translation Reserve	Total
	\$	\$	\$	\$	\$	\$	\$
Balance at 1 January 2021	14,211,972	(11,948,731)	342,620	(1,710,087)	281,662	35,505	1,212,942
Loss for the half-year	-	(1,077,573)	-	-	-	-	(1,077,573)
OCI – FX Translation	-	-	-	-	-	3,267	3,267
Total comprehensive loss for the half-year	-	(1,077,573)	-	-	-	3,267	(1,074,306)
<i>Transactions with owners in their capacity as owners:</i>							
Share based payments	-	-	-	-	117,543	-	117,543
Vesting of performance rights	15,505	-	-	-	(15,505)	-	-
Shares issued under an equity facility	591,000	-	-	-	-	-	591,000
Share issue expenses	(1,411)	-	-	-	-	-	(1,411)
Balance at 30 June 2021	14,817,066	(13,026,303)	342,620	(1,710,087)	383,700	38,772	845,768
	Issued Capital	Accumulated Losses	Option Reserve	Common Control Reserve	Share Based Payment Reserve	Foreign Currency Translation Reserve	Total
	\$	\$	\$	\$	\$	\$	\$
Balance at 1 January 2022	16,769,439	(14,269,349)	363,380	(1,710,087)	317,493	113,727	1,584,603
Loss for the half-year	-	(1,227,000)	-	-	-	-	(1,227,000)
OCI – FX Translation	-	-	-	-	-	1,737	1,737
Transfer	-	-	(20,760)	-	-	20,760	-
Total comprehensive loss for the half-year	-	(1,227,000)	(20,760)	-	-	22,497	(1,225,263)
<i>Transactions with owners in their capacity as owners:</i>							
Share based payments	-	-	-	-	16,977	-	16,977
Shares issued under an equity facility	350,000	-	-	-	-	-	350,000
Share issue expenses	(1,813)	-	-	-	-	-	(1,813)
Balance at 30 June 2022	17,117,626	(15,496,349)	342,620	(1,710,087)	334,470	136,224	724,504

The above Consolidated Statement of Statement of Changes in Equity should be read in conjunction with the accompanying notes

CONSOLIDATED STATEMENT OF CASH FLOWS

HALF-YEAR ENDED 30 JUNE 2022

	Half-Year Ended 30/06/2022	Half-Year Ended 30/06/2021
	\$	\$
Cash flows from Operating Activities		
Receipts from customers	61,957	302,488
Government grant received	19,369	50,299
Payments to suppliers and employees	(1,130,102)	(1,433,548)
Interest received	76	262
Net cash (used in) operating activities	(1,048,700)	(1,080,499)
Cash Flows from Financing Activities		
Proceeds from an equity facility	-	761,000
Share issue expenses	(1,813)	(1,411)
Net cash provided by/(used in) financing activities	(1,813)	759,589
Net increase (decrease) in cash held	(1,050,513)	(320,910)
Cash at the beginning of the financial period	2,013,365	1,147,917
Cash at the end of the financial period	962,862	827,007

The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. SIGNIFICANT ACCOUNTING POLICIES

Basis of Preparation

These general purpose financial statements for the interim half-year reporting period ended 30 June 2022 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

It is recommended that the financial statements are read in conjunction with the annual financial report for the year ended 31 December 2021 and any public announcements made by the Company during the half-year in accordance with continuous disclosure requirements arising under the Corporations Act 2001 and the ASX Listing Rules.

The interim financial statements have been approved and authorised for issue by the Board on 27 August 2022.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

Going concern

The interim financial report has been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the ordinary course of business. The Group incurred a loss for the half year ended 30 June 2022 of \$1,227,000 (2021: \$1,077,573) and net cash outflows from operating activities of \$1,048,700 (2021: \$1,080,499).

The ability of the Group to continue as a going concern is dependent on securing additional funding through either equity, debt or receipts, or a combination of all, to continue to fund its operational and technology development activities. These conditions indicate a material uncertainty that may cast a significant doubt about the Group's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

The Directors believe that there are sufficient funds available to continue to meet the Group's working capital requirements as at the date of this report and that sufficient funds will be available to finance the operations of the Group for the following reasons:

- The Directors of Nanoveu Limited have assessed the likely cash flow for the 12 month period from date of signing this half year report and its impact on the Group and believe there will be sufficient funds to meet the Group's working capital requirements as at the date of this report, based on the belief that additional funds will be receipted via product sales to finance the Company's activity.
- The Group has historically demonstrated its ability to raise funds to satisfy its immediate cash requirements. Management have considered the future capital requirements of the Group and will consider all funding options as required.
- The Directors of Nanoveu Limited have reason to believe that in addition to the cash flow currently available, additional funds from receipts are expected from the commercialisation of the Group's products.

Should the Group not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements or raise additional capital through equity or debts raisings and that the interim financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or liabilities that might be necessary should the Group not continue as a going concern and meet its debts as and when they become due and payable.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Basis of Measurement and Reporting Conventions

The financial statements, except for cash flow information, have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded off to the nearest dollar unless stated otherwise.

The accounting policies adopted are consistent with the accounting policies adopted in the Group's last annual financial statements for the year ended 31 December 2021 except for the adoption of new and amended standards adopted by the Group. Comparative figures have been adjusted to conform to changes in presentation for the current financial year.

New, revised or amending Accounting Standards and Interpretations adopted

The Group has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant or material change to the Group's accounting policies.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Functional and presentation currency

These financial statements are presented in Australian dollars, which is the functional currency of Nanoveu Limited.

Critical estimates and judgements

Performance rights

6,809,500 performance rights are on issue, at 30 June 2022, which convert into fully paid ordinary shares on the achievement of the milestones as disclosed in Note 7. If the milestone is not satisfied on or before expected achievement dates, the Performance Rights will expire.

For remuneration and expense recognition purposes the value is the number of performance rights granted, multiplied by the share price at date of grant and the value being amortised over the period to the expected vesting date after assessing the likelihood, probability and date of achieving these milestones. These are then reassessed at each reporting date for performance rights which have not been achieved nor expired.

Inventories

Inventories are valued at the lower of cost and net realisable value. Costs incurred in bringing each product to its present location and condition are accounted for, as follows:

- Raw materials: purchase cost on a first-in/first-out basis; and
- Finished goods and work in progress: cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.

Net realisable value is the estimated selling price in the ordinary course.

Financial Liabilities

The Company secured a funding facility of up to \$2.4 million from Antiviral Technologies Portfolio LLC ("the Investor") for subscriptions for ordinary shares of the Company as follows:

- A \$1,600,000 subscription for shares with the value of \$1,756,000 has been received by the Company.
- An additional \$800,000 subscription for shares with the value of \$878,000 may be made by mutual consent of the parties, subject to the Company obtaining shareholder approval for that subscription.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Each of these investments will be made by way of the Investor prepaying for shares which will be issued upon the Investor's written request, within 18 months of the final subscription, in the number determined by applying to the subscription amount prepaid for by the Investor the "Purchase Price", being the average of the five daily volume-weighted average prices (rounded down to the next one tenth of a cent, or if the share price exceeds \$0.10, the next half a cent) selected by the Investor at its discretion during the 20 consecutive actual trading days immediately prior to the Investor's written request. Each issue must be for no less than \$150,000 of the shares.

The difference between the amount received by the Company and the value of shares to be issued plus the fair value of the shares issued in lieu of fees and the fair value of the options granted to the Investor are amortised as notional interest over the term of each tranche. As ordinary shares are issued to settle the liability for shares, the liability is reduced by the value of the shares issued and the accrued finance cost is recognised through profit and loss.

Coronavirus (COVID-19) pandemic

On 31 January 2020, the World Health Organisation (WHO) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (COVID-19 outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. Because of the rapid increase in exposure globally, on 11 March 2020, the WHO classified the COVID-19 outbreak as a pandemic.

The full impact of the COVID-19 outbreak continues to evolve at the date of this report. The Group is therefore uncertain as to the full impact that the pandemic will have on its financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation and its impact on the Group's financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Group is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for the 2022 financial year.

Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Group's results of future operations, financial position, and liquidity in the fiscal year 2022 and 2023.

2. SEGMENT REPORTING

The Group predominantly deploys nanotechnology. For management purposes, the Group is organised into business units based on its services and has three reportable segments, as follows:

- Americas;
- rest of the world; and
- corporate and head office.

No operating segments have been aggregated to form the above reportable operating segments.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the consolidated financial statements. The Group's financing (including finance costs and finance income) and income taxes are managed on a Group basis and are not allocated to operating segments.

Transfer prices between operating segments are on an arm's length basis in a manner similar to transactions with third parties.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Half-year Ended 30 June 2022	Americas	Rest of the World	Corporate and Head Office	Total Segments	Adjustments and Eliminations	Consolidated
Revenue						
External customers	876	76,311	-	77,187	-	77,187
Inter-segment		-	-	-	-	-
Total revenue (i)	876	76,311	-	77,187	-	77,187
Income/(expenses)						
Depreciation and amortisation	-	(24,613)	-	(24,613)	-	(24,613)
Segment profit/(loss)	(1,177)	(493,635)	(576,914)	(1,227,000)	-	(1,227,000)
Total assets	4,654	818,509	783,636	1,606,799	-	1,606,799
Total liabilities	(6,475)	(109,086)	(770,904)	(882,295)	-	(882,295)
Half-year Ended 30 June 2021						
	Americas	Rest of the World	Corporate and Head Office	Total Segments	Adjustments and Eliminations	Consolidated
Revenue						
External customers	-	423,827	-	423,827	-	423,827
Inter-segment		-	-	-	-	-
Total revenue (i)	-	423,827	-	423,827	-	423,827
Income/(expenses)						
Depreciation and amortisation	-	(25,761)	-	(25,761)	-	(25,761)
Segment profit/(loss)	(664)	(371,513)	(705,396)	(1,077,573)	-	(1,077,573)
Total assets	103	982,914	714,747	1,697,763	-	1,697,763
Total liabilities	(266)	(162,831)	(688,899)	(851,995)	-	(851,995)

(i) Revenue is recognised at a point in time.

Adjustments and eliminations

Finance income and costs, and fair value gains and losses on financial assets are not allocated to individual segments as the underlying instruments are managed on a group basis. Current taxes and certain financial assets and liabilities are not allocated to those segments as they are also managed on a group basis. Inter-segment revenues are eliminated on consolidation.

3. LOSS PER SHARE

	Half-year Ended 30/06/2022	Half-year Ended 30/06/2021
(Loss) for the period	(\$1,227,000)	(\$1,077,573)
Weighted average number of ordinary shares used in the (loss) per share calculations	217,516,645	158,590,933
Basic and diluted (loss) per share (cents)	(0.6)	(0.7)

4. DIVIDENDS PAID OR PROPOSED

No dividends were paid or declared during the half-year ended 30 June 2022 (30 June 2021: nil).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

5. INVENTORIES

	As at 30/06/2022	As at 31/12/2021
Finished goods	18,363	3,684
Work-in-progress	527,255	465,614
	<u>545,618</u>	<u>469,298</u>

Work-in-progress comprises of raw materials being processed into finished goods.

6. FINANCIAL LIABILITIES

	As at 30/06/2022	As at 31/12/20
	\$	\$
Current:		
Advance against shares to be issued	1,600,000	1,600,000
Less: Transaction costs – options/shares	(326,314)	(326,314)
Add: Accrued finance costs	415,373	342,995
Less: Value of placement shares issued (Note 7(a))	(980,000)	(630,000)
Financial liability balance at year-end	<u>709,059</u>	<u>986,682</u>

The following placement shares were issued under the Antiviral Technologies Portfolio LLC facility agreement during the half-year period:

- 6,666,667 shares issued on 11 January 2022 for \$200,000
- 6,818,182 shares issued on 5 May 2022 for \$150,000

During the period, the Company recognised a total of \$72,377 in accrued finance costs through profit and loss.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

7. ISSUED CAPITAL

(a) Ordinary shares

	As at 30/06/2022	As at 31/12/2021
Paid up capital – ordinary shares	18,386,520	18,036,520
Capital raising costs	(1,268,894)	(1,267,081)
	17,117,626	16,769,439

	Date	Number of shares	\$
30 June 2022 movements in issued capital:			
Balance at 1 January 2022		209,071,140	16,769,439
Shares issued under an equity agreement (see Note 6)			
- Placement shares	11 Jan 2022	6,666,667	200,000
- Placement shares	5 May 2022	6,818,182	150,000
		222,555,989	17,119,439
Share issue expenses		-	(1,813)
Balance at 30 June 2022		222,555,989	17,117,626

(b) Share options

Options on issue:

At 30 June 2022, unissued ordinary shares of the Company under option were:

Terms of Options	Number on Issue
Unlisted options with an exercise price of \$0.10 on or before 22 December 2022	3,300,000
Unlisted options with an exercise price of \$0.1018 on or before 28 October 2023	3,900,000
Unlisted options with an exercise price of \$0.058 on or before 6 Sep 2023	1,000,000
Unlisted options with an exercise price of \$0.058 on or before 1 Feb 2024	15,000,000
Unlisted options with an exercise price of \$0.058 on or before 5 Oct 2023	5,902,855
Total	29,102,855

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(c) Performance rights

Performance Rights Reassessed:

The following performance rights have non-market vesting conditions, the assumed probabilities of achieving these vesting conditions have been reassessed since 31 December 2021:

Tranche	Performance Hurdle	Number	Assumed Probability of achievement	Assumed Achievement Date
K	A\$8m of sales revenue across all by 31 December 2022 as validated from audited / reviewed financial reports	2,710,000	0%	-
L	A\$15m of sales revenue across all by 31 December 2023 as validated from audited / reviewed financial reports	2,260,000	0%	-
O	A\$2.7m of EyeFyx product sales revenue by 31 December 2022 as validated from audited / reviewed financial reports	250,000	0%	-
P	A\$5m of EyeFyx product sales revenue by 31 December 2023 as validated from audited / reviewed financial reports	250,000	0%	-
Total		6,809,500		

The performance rights have a 7 year expiry date. The date at which the performance hurdle is assumed to be achieved has been estimated based on the target date for the performance hurdle to be achieved. If the milestone is not satisfied on or before expected achievement dates, the Performance Rights will expire.

8. SHARE-BASED PAYMENTS

During the half-year ended 30 June 2022 a total share-based payment expense of \$16,977 was recognised as an expense through profit and loss (30 June 2021: \$117,543).

9. RELATED PARTY TRANSACTIONS

There were no other transactions with related parties during the half-year other than those that were on the same basis as stated in the 31 December 2021 Annual Report.

10. COMMITMENTS AND CONTINGENCIES

Nanoveu and Alan Scott Industries Ltd (Alan Scott) have signed a memorandum of understanding (MoU) to establish a new company to be called Alan Scott Nanoveu India Limited (ASNIL) which will have a paid-up capital of US\$200,000 and be 35% owned by Nanoveu. The MoU shall terminate on 31 December 2022 unless agreed otherwise by the parties.

Commercial terms will be negotiated and finalised during the period the MoU is in place following which a definitive agreement is expected to be signed which will see ASNIL buy Nanoshield products from Nanoveu and sell these in India utilising Alan Scott's existing networks and retail outlets.

There have been no other changes in commitments or contingent liabilities since the last annual reporting date.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

11. IMPAIRMENT

The following assets were impaired as management assessed that their value was not recoverable:

	Half-year Ended 30/06/2022	Half-year Ended 30/06/2021
Investment in joint arrangement ¹	100,724	-
	<u>100,724</u>	<u>-</u>

¹During the half-year the Company recognised an impairment expense of \$100,724 relating to an investment in joint arrangement. This balance was included within other receivables at 31 December 2021.

12. EVENTS AFTER THE BALANCE SHEET DATE

Subsequent to reporting date the Company issued 10,714,286 shares at \$0.014 retiring \$150,000 of debt of the Company and Non-executive director, Mr Scott Beeton, retired effective 31 August 2022.

The impact of the Coronavirus (COVID-19) pandemic is ongoing and it is not practicable to estimate the potential impact, positive or negative, after the reporting period. The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

Apart from the items above, no matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs in future financial years.

DIRECTORS' DECLARATION

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2022 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



Mr Alfred Chong
Managing Director and CEO
31st August 2022

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Nanoveu Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of Nanoveu Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2022, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- (i) Giving a true and fair view of the Group's financial position as at 30 June 2022 and of its financial performance for the half-year ended on that date; and
- (ii) Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

Material uncertainty relating to going concern

We draw attention to Note 1 in the financial report which describes the events and/or conditions which give rise to the existence of a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business. Our conclusion is not modified in respect of this matter.

Responsibility of the directors for the financial report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including giving a true and fair view of the Company's financial position as at 30 June 2022 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit (WA) Pty Ltd



Jackson Wheeler

Director

Perth

31 August 2022